No Prescription |
 |
 | ||
|
Apo Oxybutynin Syrup Ditropan |
|
| ||
No Prescription » Prescription Drugs 2 » Apo Oxybutynin Syrup Ditropan IndicationsOxybutynin chloride is primarily indicated for the management of urgency and incontinence that characterise neurogenic bladder disorders and idiopathic detrusor instabilityDosage and AdministrationAPO-OXYBUTYNIN is not recommended for children under 5 years.Pre-treatment examination should include cystometry and other appropriate diagnostic procedures. Cystometry should be repeated at appropriate intervals to evaluate response to therapy. Appropriate antimicrobial therapy should be instituted in the presence of infectionAdults:The usual dosage is 5mg taken 2 to 3 times daily. The maximum recommended dose is 5mg taken 4 times daily.Elderly patients:Initially treatment should be 2.5mg taken 2 times daily and increased as necessary.Children over 5 years:The usual dosage is 5mg taken twice daily. The maximum recommended dose is 5mg taken 3 times daily. Buy Apo Oxybutynin Syrup Ditropan and other Prescription Drugs 2 products online at Medstore. 5563
About Apo Oxybutynin Syrup Ditropan: Product Type: Prescription Drugs 2 Apo-Oxybutynin Syrup ( Ditropan Generic Oxybutynin ) Apo-Oxybutynin Syrup (Ditropan Generic Oxybutynin) Ditropan Generic Oxybutynin 5mg/5mL 473mL Ditropan Generic Oxybutynin Apo-Oxybutynin Syrup
View more Prescription Drugs 2 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
